Aya El Helali, Principal Investigator at the Centre for Oncology and Immunology, Clinical Assistant Professor at The University of Hong Kong, and Vice President of the Hong Kong Neuro-Oncology Society, shared a post on X:
“Just back from ESMO25! Latest in glioma treatment:
- SCOUT trial’s ‘watch-and-see’ NTRK inhibitor approach (challenge: when to pause?)
- IL13Ra2 CART cells – progress but TME/antigen escape hurdles
- Procaspase 3: apoptosis revival?”
Follow the latest ESMO 2025 news on OncoDaily.
